ADC Development for Pancreatic Cancers

Pancreatic cancer represents one of the most lethal solid tumors, which is notoriously refractory to chemotherapy. Thus, the therapy outcome for patients with pancreatic cancer is still poor. A large number of new treatment approaches are being investigated actively, and antibody-drug conjugates (ADCs) showing unique advantages has been widely assessed in the treatment of pancreatic cancer.

Creative Biolabs is one of the leaders in the field of biotherapeutic drug development. Our scientists have obtained extensive experience through years of cooperation with customers across the world. Our comprehensive ADCs system offers a wide range of ADCs design and construction services against the pancreatic cancer. Our services will assist customers in candidate selection and optimization in different phases of ADCs drug development.

Introduction of Pancreatic Cancers

Pancreatic cancer is a type of solid tumors occurring in the pancreas that an organ in the abdomen. Pancreas mainly involves in the release of enzymes that facilitates digestion and help maintain blood sugar level. Currently, pancreatic cancer is the eighth most frequent solid tumor in the world and frequently causing deaths. Pancreatic cancer is divided into a variety of types. Pancreatic adenocarcinoma is the most common representing 85% of cases. Commonly, signs and symptoms of pancreatic cancer include the pain in the upper abdomen, loss of appetite or unexplained weight loss, depression, diabetes, blood clots, fatigue and yellowing of skin and the jaundice. Risk factors of the cancer include chronic inflammation of the pancreas, diabetes, family history of genetic syndromes and pancreatic cancer, smoking, obesity and older age. So far, the treatment for pancreatic cancer relies on the stage, the location of the cancer and the overall health and personal preferences. Treatments options mainly include the surgery, radiation, chemotherapy currently.

Pancreatic cancer. Fig.1 Pancreatic cancer.

Current Therapeutic Strategies for Pancreatic Cancers

To date, the treatment strategies of pancreatic cancer mainly include conventional options such as the chemotherapy, the radiation and the combined use of radiation and chemotherapy. Chemotherapy drugs such as the 5-fluorouracil (5-FU), platinum or nitroso-urea, can significantly increase median survival of patients with pancreatic cancer. However, the relatively low response rates indicate that some novel treatment agents are essential. Some novel agents and enzymes include Matrix metalloproteinase inhibitors, polyamine analogues, topoisomerase I inhibitors, nucleoside analogues, carbohydrates, acylfulvenes, digestive enzymes, hormonal therapies and enzyme inhibitors.

In addition, a variety of novel immunological strategies also have been developed. Monoclonal antibodies represent one of the most promising agents. For example, the SB408075 is a humanized mAb that recognizes C242 overexpressed on the pancreatic cancers cells. Cetuximab is another antibody can specifically recognize EGFR that present on many pancreatic cancers, and it has been investigated in a Phase II trial in patients with EGFR positive tumors. ADCs are another type of immunotherapy used in the pancreatic cancers. To date, several ADCs have been designed such as the RG7882 (DMUC406A), RG7600 (DMOT4039A), AbGn-107, and Cantuzumab ravtansine (IMGN242).

Other immunotherapies include virulizin, granulocyte-macrophage colony stimulating factor transfected allogeneic tumour cells, therapeutic vaccines and heat-shock protein-peptide vaccination. Besides, other novel strategies for the treatment of pancreatic cancer include antisense nucleic acids, expression of dominant-negative mutants, delivery of somatostatin receptor gene, suicide gene strategies and targeting of p53-deficient cells.

Current and emerging therapies in pancreatic cancers. Fig.2 Current and emerging therapies in pancreatic cancers. (Manji, 2017)

What Can We Do for You?

Creative Biolabs is dedicated to offering one-stop ADCs development services targeting the pancreatic cancer. Our services are highly flexible addressing your special demands and our experienced experts will work in close collaboration with your team to effectively support your ADCs construction. Targets of ADC development for pancreatic cancers:

If you are interested in our featured services, please contact us for more information and a detailed quote. We are looking forward to working together with your attractive projects.

Reference

  1. Manji, G. A.; et al. Current and emerging therapies in metastatic pancreatic cancer. 2017, 1670-1678.


Online Inquiry
Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.


Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.


Contact us
USA
 45-1 Ramsey Road, Shirley, NY 11967, USA
 Tel: 1-631-357-2254
 Fax: 1-631-207-8356
 Email:
Europe
Heidenkampsweg 58, 20097 Hamburg, Germany
 Tel: 44-207-097-1828
 Email:

Inquiry

Top